GSK updates share capital and voting rights total

GSK plc reports its share capital and voting rights position as of 31 January 2026.

Rhea-AI Filing Summary

GSK plc reports its share capital and voting rights position as of 31 January 2026. The company had 4,316,103,805 ordinary shares of 31¼ pence each in issue, with 240,019,489 shares held in treasury. This leaves 4,076,084,316 voting rights currently available to shareholders.

Shareholders can use this voting rights figure as the denominator when calculating whether they must notify new or changed holdings under UK disclosure rules.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What total voting rights did GSK (GSK) report as of 31 January 2026?

GSK reported 4,076,084,316 total voting rights as of 31 January 2026. This reflects all ordinary shares in issue excluding those held in treasury and is the key number investors use for regulatory shareholding disclosure calculations.

How many GSK (GSK) shares were in issue and in treasury?

As of 31 January 2026, GSK had 4,316,103,805 ordinary shares in issue, each with a nominal value of 31¼ pence. Of these, 240,019,489 shares were held in treasury and therefore do not carry voting rights in shareholder calculations.

Why does GSK’s (GSK) total voting rights figure matter for investors?

The 4,076,084,316 voting rights figure is used as the denominator when investors calculate their percentage ownership. This helps determine whether they must notify new or changed positions under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.

What type of shares does GSK (GSK) have in its issued share capital?

GSK’s issued share capital consists of ordinary shares of 31¼ pence each. These ordinary shares represent the company’s equity, carry voting rights when not held in treasury, and form the basis for ownership and regulatory disclosure calculations by shareholders.

How can GSK (GSK) shareholders notify changes in their shareholding interests?

Shareholders can notify GSK of interests or changes by emailing company.secretary@gsk.com. Notifications are required under the UK Financial Conduct Authority’s Disclosure Guidance and Transparency Rules when certain ownership thresholds, based on total voting rights, are crossed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/02/2026 - 01:42 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of February 2026

Commission File Number 001-15170

GSK plc

(Translation of registrant's name into English)

79 New Oxford Street, London, WC1A 1DG

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F . . . .X. . . . Form 40-F . . . . . . . .

Issued: 2 February 2026, London UK

Total Voting Rights

In conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R, GSK plc (the 'Company') hereby notifies the market of the following:

The Company's issued share capital as at 31 January 2026 consisted of 4,316,103,805 shares of 31 ¼ pence each ('Ordinary Shares'), of which 240,019,489 Ordinary Shares were held in Treasury.

Therefore, the total number of voting rights in the Company is 4,076,084,316. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Notifications may be sent to company.secretary@gsk.com.

V A Whyte

Company Secretary

2 February 2026

About GSK

GSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at www.gsk.com.

Registered in England & Wales:

No. 3888792

Registered Office:

79 New Oxford Street

London

WC1A 1DG

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GSK plc

(Registrant)

Date: February 02, 2026

By:/s/ VICTORIA WHYTE

--------------------------

Victoria Whyte

Authorised Signatory for and on

behalf of GSK plc